Eisai wins latest round in Japanese Aricept patent extension case
This article was originally published in Scrip
The Intellectual Property High Court of Japan has upheld a decision by the country's Patent Office to grant an extension to the local patent for Eisai's Aricept (donepezil) in relation to its use in severe Alzheimer's dementia.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.